Total Voting Rights

3 October 2016 15:00

Transparency Directive

Voting Rights and Capital

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 30 September 2016 the issued share capital of AstraZeneca PLC with voting rights is 1,265,021,933 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,265,021,933.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media   Enquiries
Neil   Burrows UK/Global +44 203 749 5637
Vanessa   Rhodes UK/Global +44 203 749 5736
Karen   Birmingham UK/Global +44 203 749 5634
Rob   Skelding UK/Global +44 203 749 5821
Jacob   Lund Sweden +46 8 553 260 20
Michele   Meixell US +1 302 885 2677
Investor Relations
UK
Thomas Kudsk Larsen +44 203 749 5712
Craig   Marks Finance,   Fixed Income, M&A +44 7881 615 764
Nick   Stone Respiratory   & Autoimmunity +44 203 749 5716
Henry   Wheeler Oncology +44 203 749 5797
Christer   Gruvris Infection   & Neuroscience +44 203 749 5711
US
Lindsey   Trickett Cardiovascular   & Metabolic Diseases +1 240 543 7970
Mitchell   Chan Oncology +1 240 477 3771
Toll-free +1 866 381 7277

Adrian Kemp
Company Secretary
AstraZeneca PLC

-ENDS-

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links